Off-label biologics use and infection risk—the great unknown

The use of biologic therapies for off-label conditions in daily clinical practice is increasing, yet few studies have detailed the safety of these agents with regards to infection in

patients with systemic autoimmune disease. New research offers a glimpse at the infection rates in these vulnerable patients. Access through your institution Buy or subscribe This is a

preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per

year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Díaz-Lagares, C. _ et al_. Rates of, and

risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. _Arthritis Res. Ther._ 13, R112 (2011). Article  Google Scholar  *

Furst, D. E. _ et al_. Updated consensus statement on biological agents for the treatment of rheumatic diseases. _Ann. Rheum. Dis._ 70 (Suppl. 1), i2–i36 (2011). Article  Google Scholar  *

Carmona, L. _ et al_. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. _Rheumatology_ 50, 85–92 (2011).

Article  CAS  Google Scholar  * Bongartz, T. _ et al_. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and

meta-analysis of rare harmful effects in randomized controlled trials. _JAMA_ 295, 2275–2285 (2006). Article  CAS  Google Scholar  * Dixon, W. G. _ et al_. Serious infection following

anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. _Arthritis Rheum._ 56, 2896–2904 (2007). Article 

CAS  Google Scholar  * Curtis, J. R. _ et al_. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. _Ann. Rheum. Dis._ 70,

1401–1406 (2011). Article  CAS  Google Scholar  * Ippolito, A & Petri, M. An update on mortality in systemic lupus eruthematous patients. _Clin. Exp. Rheum._ 26, S72–S79 (2008). CAS 

Google Scholar  * Terrier, B. _ et al_. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.

_Arthritis Rheum._ 62, 2458–2466 (2010). Article  CAS  Google Scholar  * Terrier, B. _ et al_. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French

Autoimmunity and Rituximab registry. _Arthritis Care Res. (Hoboken)_ 62, 1787–1795 (2010). Article  CAS  Google Scholar  * Stone, J. H. _ et al_. Solid malignancies among patients in the

Wegener's Granulomatosis Etanercept Trial. _Arthritis Rheum._ 54, 1608–1618 (2006). Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *

Divisions of Infectious Diseases, and Public Health and Preventive Medicine, Oregon Health and Sciences University, 3375 SW Terwilliger Blvd, Portland, 97239, OR, USA Kevin L. Winthrop *

Division of Rheumatology, Department of Medicine, Medical University of Vienna, Waeringer Guertel 18–20, Vienna, A1090, Austria Josef S. Smolen Authors * Kevin L. Winthrop View author

publications You can also search for this author inPubMed Google Scholar * Josef S. Smolen View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING

AUTHOR Correspondence to Kevin L. Winthrop. ETHICS DECLARATIONS COMPETING INTERESTS K. L. Winthrop has acted as a consultant for Abbott, Amgen, Genentech and Lilly, and has received

grant/research support and acted as a consultant for Pfizer. J. S. Smolen has acted as a consultant and received grant/research support from Bristol–Myers Squibb, Centour, MSD, Pfizer,

Roche, UCB. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Winthrop, K., Smolen, J. Off-label biologics use and infection risk—the great unknown. _Nat

Rev Rheumatol_ 7, 685–686 (2011). https://doi.org/10.1038/nrrheum.2011.154 Download citation * Published: 11 October 2011 * Issue Date: December 2011 * DOI:

https://doi.org/10.1038/nrrheum.2011.154 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative